Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Charles River Laboratories International Inc (NYSE:CRL)

Delayed Data
As of 4:02pm ET
 +0.92 / +1.09%
Today’s Change
Today|||52-Week Range
Health Technology

Company Description

Charles River Laboratories International, Inc. is an early-stage contract research company, which provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe to accelerate their research and drug development efforts. It operates through the following business segments: Research Models and Services, Discovery and Safety Assessment, and Manufacturing Support. The Research Models and Services segment comprises of the production and sale of research models, and also offers services designed to support to clients use of research models in screening drug candidates. The Discovery and Safety Assessment segment offers discovery and safety assessment services, both regulated and non-regulated, in which it include both in vivo and in vitro studies, supporting laboratory services, and strategic preclinical consulting and program management to support product development. The Manufacturing Support segment offers endotoxin and microbial detection, avian vaccine services and biologics testing solutions. The company was founded by Henry L. Foster in 1947 and is headquartered in Wilmington, MA.

Contact Information

Charles River Laboratories International, Inc.
251 Ballardvale Street
Wilmington Massachusetts 01887
P:(781) 222-6000
Investor Relations:
(781) 222-6190



Other institutional51.05%
Mutual fund holders50.33%
Individual stakeholders4.11%

Top Executives

James C. FosterChairman, President & Chief Executive Officer
David R. SmithChief Financial Officer & Executive Vice President
Shanna L. Cotti-OsmanskiChief Information Officer
Davide A. MolhoEVP, President-Global Research Models & Services
Brian BathgateSenior VP & President-European Preclinical Service